Search Results - "MOLITERNO, D. J"

Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes by McCarthy, J J, Parker, A, Salem, R, Moliterno, D J, Wang, Q, Plow, E F, Rao, S, Shen, G, Rogers, W J, Newby, L K, Cannata, R, Glatt, K, Topol, E J

“…Background: to date, only three groups have reported data from large scale genetic association studies of coronary heart disease using a case control design…”
Get full text

Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy by Roffi, M., Chew, D.P., Mukherjee, D., Bhatt, D.L., White, J.A., Moliterno, D.J., Heeschen, C., Hamm, C.W., Robbins, M.A., Kleiman, N.S., Théroux, P., White, H.D., Topol, E.J.

“…Aims To assess the efficacy of platelet glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes primarily medically managed. Methods and…”
Get full text

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease by KONG, D. F, CALIFF, R. M, MILLER, D. P, MOLITERNO, D. J, WHITE, H. D, HARRINGTON, R. A, TCHENG, J. E, LINCOFF, A. M, HASSELBLAD, V, TOPOL, E. J

“…Several platelet glycoprotein (GP) IIb/IIIa receptor antagonists have been evaluated in clinical trials. We conducted a systematic overview (meta-analysis) to…”
Get full text

Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes by Roe, M.T., Mahaffey, K.W., Kilaru, R., Alexander, J.H., Akkerhuis, K.M., Simoons, M.L., Harrington, R.A., Tardiff, B.E., Granger, C.B., Ohman, E.M., Moliterno, D.J., Lincoff, A.M., Armstrong, P.W., Van de Werf, F., Califf, R.M., Topol, E.J.

“…Aim To study the relationship between outcomes and peak creatine kinase (CK)-MB levels after percutaneous coronary intervention (PCI) in patients with…”
Get full text

Increased mortality among patients taking digoxin--analysis from the AFFIRM study by Whitbeck, Matthew G, Charnigo, Richard J, Khairy, Paul, Ziada, Khaled, Bailey, Alison L, Zegarra, Milagros M, Shah, Jignesh, Morales, Gustavo, Macaulay, Tracy, Sorrell, Vincent L, Campbell, Charles L, Gurley, John, Anaya, Paul, Nasr, Hafez, Bai, Rong, Di Biase, Luigi, Booth, David C, Jondeau, Guillaume, Natale, Andrea, Roy, Denis, Smyth, Susan, Moliterno, David J, Elayi, Claude S

“…Digoxin is frequently used for rate control of atrial fibrillation (AF). It has, however, been associated with increased mortality. It remains unclear whether…”
Get full text

Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study by McGuire, D.K, Emanuelsson, H, Granger, C.B, Magnus Ohman, E, Moliterno, D.J, White, H.D, Ardissino, D, Box, J.W, Califf, R.M, Topol, E.J

“…Aims We examined the characteristics, outcomes, and effects of hirudin vs heparin treatment of diabetic patients across the spectrum of acute coronary…”
Get full text

Association of genetic variants in the HDL receptor, SR-B1, with abnormal lipids in women with coronary artery disease by McCarthy, J J, Lehner, T, Reeves, C, Moliterno, D J, Newby, L K, Rogers, W J, Topol, E J

“…HDL-C has been shown to correlate with LDL particle size 12 and is a powerful predictor of future myocardial infarction. 13 The scavenger receptor class B type…”
Get full text

Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment by Mukherjee, D, Topol, E J, Moliterno, D J, Brennan, D M, Ziada, K, Cho, L, Steinhubl, S R

“…Objective: To assess the effectiveness of long term treatment with clopidogrel of patients with extracardiac vascular disease (ECVD) (a history of either…”
Get full text

Subacute stent thrombosis: Evolving issues and current concepts by Mak, Koon-Hou, Belli, Guido, Ellis, Stephen G., Moliterno, David J.

“…During percutaneous coronary revascularization, intracoronary stents are effective in the treatment of abrupt vessel closure and improvement of suboptimal…”
Get full text

Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention by STEINHUBL, S. R, KOTTKE-MARCHANT, K, MOLITERNO, D. J, ROSENTHAL, M. L, GODFREY, N. K, COLLER, B. S, TOPOL, E. J, LINCOFF, A. M

“…Although the effectiveness of abciximab (c7E3 Fab; ReoPro) in large populations of patients undergoing a percutaneous coronary intervention has been…”
Get full text

Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials by Valgimigli, Marco, Biondi-Zoccai, Giuseppe, Tebaldi, Matteo, van 't Hof, Arnoud W.J., Campo, Gianluca, Hamm, Christian, ten Berg, Jurriën, Bolognese, Leonardo, Saia, Francesco, Danzi, Gian Battista, Briguori, Carlo, Okmen, Ertan, King, Spencer B., Moliterno, David J., Topol, Eric J.

“…Aims To perform a thorough and updated systematic review of randomized clinical trials comparing tirofiban vs. placebo or vs. abciximab. Methods and results We…”
Get full text

Safety and efficacy of protease‐activated receptor‐1 antagonists in patients with coronary artery disease: a meta‐analysis of randomized clinical trials by CAPODANNO, D., BHATT, D. L., GOTO, S., O’DONOGHUE, M. L., MOLITERNO, D. J., TAMBURINO, C., ANGIOLILLO, D. J.

“…Background:  Thrombin receptor antagonists blocking protease‐activated receptor‐1 (PAR‐1) on platelets represent a new class of oral antiplatelet agents for…”
Get full text

Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes by Asher, Craig R., Topol, Eric J., Moliterno, David J.

“…Background Disparities in prognosis for black and white patients with coronary heart disease have been widely reported. For several reasons it is unclear to…”
Get full text

The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non–Q-wave myocardial infarctions by Steinhubl, Steven R, Lauer, Michael S, Mukherjee, Debabrata P, Moliterno, David J, Lincoff, A. Michael, Ellis, Stephen G, Topol, Eric J

“…Objectives. This study sought to determine whether the duration of pretreatment with the adenosine diphosphate receptor antagonist ticlopidine prior to…”
Get full text

Coronary-Artery Vasoconstriction Induced by Cocaine, Cigarette Smoking, or Both by Moliterno, David J, Willard, John E, Lange, Richard A, Negus, Brian H, Boehrer, James D, Glamann, D. Brent, Landau, Charles, Rossen, James D, Winniford, Michael D, Hillis, L. David

“…Over the past decade, cocaine abuse has become widespread, with over 30 million Americans estimated to have used it 1 . As its use has escalated,…”
Get full text

Troponins in Acute Coronary Syndromes: More TACTICS for an Early Invasive Strategy by Quinn, Martin J, Moliterno, David J

“…Cardiac isoforms of troponin I (CTNI) AND T (cTnT) are highly sensitive and specific markers of myocardial injury. The prognostic importance of these markers…”
Get full text

Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor by Wallace, RC, Furlan, AJ, Moliterno, DJ, Stevens, GH, Masaryk, TJ, Perl, J, 2nd

“…We describe the use of abciximab to prevent rethrombosis of the basilar artery after transluminal angioplasty. A 60-year-old patient with vertebral basilar…”
Get full text

Racial differences in the management of unstable angina: Results from the multicenter GUARANTEE registry by Scirica, Benjamin M., Moliterno, David J., Every, Nathan R., Anderson, H.Vernon, Aguirre, Frank V., Granger, Christopher B., Lambrew, Costas T., Rabbani, LeRoy E., Sapp, Shelly K., Booth, Joan E., Ferguson, James J., Cannon, Christopher P.

“…Background Prior studies, usually conducted with the use of insurance databases, have shown differences in the use of cardiac procedures between black patients…”
Get full text

Pronounced benefit of coronary Stenting and adjunctive Platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions by CURA, F. A, BHATT, D. L, TOPOL, E. J, LINCOFF, A. M, KAPADIA, S. R, LALLIER, P. L, ZIADA, K. M, WOLSKI, K. E, MOLITERNO, D. J, BRENER, S. J, ELLIS, S. G

“…Previous trials testing stents compared with balloon angioplasty excluded patients with complex lesions and did not assess the effect of adjunctive platelet…”
Get full text

First chronic platelet glycoprotein IIb/IIIa integrin blockade : A randomized, placebo-controlled pilot study of Xemilofiban in unstable angina with percutaneous coronary interventions by SIMPFENDORFER, C, KOTTKE-MARCHANT, K, RAYMOND, R. E, SUTTON, J. M, TOPOL, E. J, LOWRIE, M, ANDERS, R. J, BURNS, D. M, MILLER, D. P, COVE, C. S, DEFRANCO, A. C, ELLIS, S. G, MOLITERNO, D. J

“…Clinical studies have demonstrated the efficacy of intravenous administration of agents that block platelet glycoprotein IIb/IIIa receptors in the setting of…”
Get full text